Document:

<PAGE>
                                                                   Exhibit 10.87

                    ASSIGNMENT OF COMMERCIALIZATION AGREEMENT

      This is an Agreement, effective as of the 1st day of April, 1995 (the
EFFECTIVE DATE), among Coulter Pharmaceutical, Inc., a corporation incorporated
in the State of Delaware, with offices located at 550 California Avenue, Suite
200, Palo Alto, California 94306-1440 ("CPI"); Coulter Corporation, a
corporation incorporated in the State of Delaware, with offices located at 11800
S.W. 147 Avenue, Miami, Florida 33196 ("COULTER"); and the Regents of the
University of Michigan, a constitutional corporation of the State of Michigan,
with offices located at 3003 South State, Room 2071, Ann Arbor, Michigan
48109-1280 ("MICHIGAN"). CPI, COULTER and MICHIGAN agree as follows:

1.    BACKGROUND

1.1   MICHIGAN and COULTER have previously entered into a COMMERCIALIZATION
        AGREEMENT, attached hereto and incorporated herein as the Attachment,
        covering certain TECHNOLOGY and LICENSED PATENTS as therein defined.

1.2   COULTER wishes to assign all of its rights and obligations under the
        COMMERCIALIZATION AGREEMENT to CPI, and CPI wishes to accept such
        assignment. As required by the COMMERCIALIZATION AGREEMENT, and
        consistent with its mission of education and research, MICHIGAN wishes
        to consent to such assignment.

2.    ASSIGNMENT

2.1   COULTER hereby assigns all of its rights and obligations under the
        COMMERCIALIZATION AGREEMENT to CPI.

2.2   CPI hereby accepts this Assignment, all of the terms and conditions of the
        COMMERCIALIZATION AGREEMENT, and all of COULTER'S rights and obligations
        under the COMMERCIALIZATION AGREEMENT,

2.3   MICHIGAN hereby accepts this Assignment.

2.4   COULTER, CPI and MICHIGAN acknowledge that the parties to the
        COMMERCIALIZATION AGREEMENT henceforth are CPI and MICHIGAN. Obligations
        fully satisfied by COULTER, such as the license issue fee, shall be
        deemed performed by CPI.

2.5   COULTER'S rights and obligations under the COMMERCIALIZATION AGREEMENT
        shall be deemed to have been terminated in accordance Article 13, as if
        the COMMERCIALIZATION AGREEMENT had been voluntarily terminated by
        notice of COULTER according to Paragraph 13.4. If CPI thereafter
        terminates the COMMERCIALIZATION AGREEMENT for any reason under
        Paragraph 13.4, then MICHIGAN shall notify COULTER and COULTER shall be
        entitled, for 60 days following such notice, to assume the rights and
        obligations of CPI to the COMMERCIALIZATION AGREEMENT.
<PAGE>
      IN WITNESS WHEREOF, the PARTIES hereto have executed this Agreement in
duplicate originals by their duly authorized officers or representatives.

COULTER PHARMACEUTICAL, INC.       THE REGENTS OF THE UNIVERSITY OF MICHIGAN

/s/ ARNOLD ORONSKY                 /s/ ROBERT L. ROBB
-------------------------------    --------------------------------------------
Title: CEO                         Title: Director, Technology Management Office

COULTER CORPORATION

 /s/ SUE VAN
-------------------------------------
Chief Financial Officer and Treasurer<PAGE>
                                                                  Exhibit 10.88

*Certain confidential information contained in this document, marked by
brackets, has been omitted and filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended

                   AMENDMENT TO COMMERCIALIZATION AGREEMENT

      This Amendment, effective as of the 1st day of June, 1997 (the EFFECTIVE
DATE), between Coulter Pharmaceutical Inc., a corporation incorporated in the
State of Delaware, with offices located at 550 California Avenue, Suite 200,
Palo Alto, California 94305-1440 ("CPI") and the Regents of the University of
Michigan, a constitutional corporation of the State of Michigan, with offices
located at 3003 South State, Room 2071, Ann Arbor, Michigan 48109-1280
("MICHIGAN"). CPI and MICHIGAN agree as follows:

1.    BACKGROUND

      1.1 MICHIGAN and Coulter Corporation entered into a COMMERCIALIZATION
AGREEMENT dated November 1, 1994 covering certain TECHNOLOGY and LICENSED
PATENTS as therein defined.

      1.2 All of Coulter Corporation rights and obligations under the
COMMERCIALIZATION AGREEMENT were assigned to CPI pursuant to an ASSIGNMENT OF
COMMERCIALIZATION AGREEMENT dated April 1, 1995, executed among Coulter
Corporation, CPI and MICHIGAN.

      1.3 MICHIGAN has developed ADDITIONAL TECHNOLOGY comprising information
covering [*] as developed by its staff members [*], as described in Michigan's
Technology Management Office File [*] (hereinafter defined as "ADDITIONAL
TECHNOLOGY"). The ADDITIONAL TECHNOLOGY is now the subject of additional United
States patent application serial numbers [*] (hereinafter these and all other
patent applications and patents which cover an invention included in the
ADDITIONAL TECHNOLOGY shall be defined as "ADDITIONAL LICENSED PATENTS").

      1.4 MICHIGAN and CPI believe that exclusive rights are an important factor
with regard to the ability to market LICENSED PRODUCTS) as defined in the
COMMERCIALIZATION AGREEMENT, and both Parties have determined that in order to
best effectuate the commercialization of the LICENSED PRODUCT(S), that exclusive
rights to the ADDITIONAL TECHNOLOGY and ADDITIONAL LICENSED PATENTS needs to be
held and promoted by CPI pursuant to the COMMERCIALIZATION AGREEMENT. To this
end, and for the benefit of both parties, MICHIGAN and CPI agree to amend the
COMMERCIALIZATION AGREEMENT as follows:

2.    AMENDMENT TO THE DEFINITIONS

      2.1 The term TECHNOLOGY shall include the ADDITIONAL TECHNOLOGY, and the
term LICENSED PATENTS shall include the ADDITIONAL LICENSED PATENTS, with the
following limitations:

            2.1.1 The Field of Use, with respect to the ADDITIONAL TECHNOLOGY
and the ADDITIONAL LICENSED PATENTS, shall be limited to the [*];

----------------------------
* Confidential treatment requested
<PAGE>
            2.1.2 MICHIGAN's covenant under Paragraph 3.1 (Commercialization
Agreement) shall apply only to the license of the ADDITIONAL TECHNOLOGY and the
ADDITIONAL LICENSED PATENTS within the Field of Use;

            2.1.3 Article 9 (Commercialization Agreement) shall not apply to
ADDITIONAL LICENSED PATENTS; and

            2.1.4 Article 10 (Commercialization Agreement) shall apply to
ADDITIONAL LICENSED PATENTS only with respect to infringements by third parties
(or actions for declaratory judgment of non-infringement or invalidity) relating
to the Field of Use.

      2.2 If new technology is developed by MICHIGAN which comprises information
and inventions that (1) are made by MICHIGAN'S faculty member [*] or employees
working under his direction, (2) are made prior to the first commercial sale of
any LICENSED PRODUCTS, (3) are not subject to conflicting option rights, license
rights or other contractual rights at the time created, and (4) contribute to
the potential use of LICENSED PRODUCTS for the [*], then MICHIGAN shall grant
rights to CPI to such technology equivalent to the rights granted to ADDITIONAL
TECHNOLOGY in Paragraph 2.1 above, except on a non-exclusive basis and [*]. CPI
shall [*].

3.    CONSIDERATION

      3.1 CPI shall [*]. The parties acknowledge that CPI has reimbursed
MICHIGAN the sum of [*] for the cost of United States patent prosecution. [*].
Expenses shall include [*].

      3.2 If MICHIGAN should license the ADDITIONAL LICENSED PATENTS and/or
ADDITIONAL TECHNOLOGY for a field of use [*], the licensee shall [*].

      3.3 The parties acknowledge that because the United States Food and Drug
Administration has approved of the viability of the ADDITIONAL TECHNOLOGY
relating to [*], CPI agrees to pay MICHIGAN the sum of [*].

      3.4 Upon the first commercial sale of the LICENSED PRODUCT(S), CPI agrees
to pay MICHIGAN an additional sum of [*].

4.    ENTIRE AGREEMENT

      4.1 The terns and conditions of the COMMERCIALIZATION AGREEMENT shall
remain in full force and effect, except as amended herein.

----------------------------
* Confidential treatment requested
<PAGE>
      IN WITNESS WHEREOF, the PARTIES hereto have executed this Amendment in
duplicate originals by their duly authorized officers or representatives.

COULTER PHARMACEUTICAL INC.               THE REGENTS OF THE
                                          UNIVERSITY OF MICHIGAN

By:  /s/ MICHAEL F. BIGHAM                By: /s/ ROBERT L. ROBB
     (authorized representative)               (authorized representative)

Typed Name Michael F. Bigham              Typed Name Robert L. Robb

Title President and CEO                   Title Director, Technology
                                          Management Office<PAGE>
                                                                   Exhibit 10.89

                             AMENDMENT NO. 1 TO THE
                               RESEARCH AGREEMENT

      This Amendment No. 1 to the Research Agreement (this "Amendment"),
effective as of March 31, 2002 (the "Effective Date"), is made by and between
Corixa Corporation, a Delaware corporation ("Corixa"), and Infectious Disease
Research Institute, a Washington not-for-profit corporation ("IDRI").

                                    RECITALS

      WHEREAS, the Parties hereto have entered into that certain Research
Agreement, effective as of March 26, 1999, (the "Agreement"); and

      WHEREAS, the parties desire to extend the Research Program Term and update
certain provisions in the Agreement;

      NOW, THEREFORE, the parties hereby agree to amend the Agreement as
follows:

1.    Unless defined otherwise herein, capitalized terms used in this Amendment
shall have the meanings given them in the Agreement.

2.    The Research Program Term shall be extended through March 31, 2003.

3.    Section 3 shall be amended and replaced in its entirety with the
      following:

            The parties hereby create a Research Oversight Committee (the
      "Research Oversight Committee") which shall consist of four (4) members,
      two (2) appointed by Corixa and two (2) appointed by IDRI. Corixa's
      initial members of the Research Oversight Committee shall be Martin
      Cheever and Kenneth Grabstein. IDRI's initial members of the Research
      Oversight Committee shall be David Webster and Patricia Wahl. Each party
      may at any time upon written notice replace one or both of its appointees
      with members reasonably acceptable to the other party. The Research
      Oversight Committee shall meet on an ad hoc basis, as agreed upon by the
      Research Oversight Committee members, during the Research Program Term to
      review the progress of the Research Program and the use of the Research
      Funds. Within thirty (30) days following each meeting, the members of the
      Research Committee shall distribute to each party minutes detailing the
      matters reviewed at such meeting.

4.    Except as amended hereby, the Agreement shall continue in full force and
effect in accordance with its terms.

5.    This Amendment shall be governed by and construed under the laws of the
State of Washington without giving effect to the principles of conflicts of
laws.

      IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed as of the date first written above.

         CORIXA CORPORATION                    INFECTIOUS DISEASE RESEARCH
                                               INSTITUTE

         /s/ STEVEN GILLIS                     /s/ DAVID WEBSTER
         ------------------------------        ------------------------------
         Steven Gillis, Ph.D.                  David Webster
         Chairman and CEO                      President

                                   Page 1 of 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}]]